Art. -Nr.: HY-10562A

Ketanserin tartrate

Name: Ketanserin tartrate
Brand: MedChemExpress
SKU: HY-10562A
Price: 55.00 USD
Availability: InStock
Rating: 5 (18 reviews)

(Synonyms: R41468 tartrate)

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

Ketanserin (R41468) tartrate is a selective 5-HT2 receptor antagonist. Ketanserin tartrate also blocks hERG current (I_hERG) in a concentration-dependent manner (IC₅₀=0.11 μM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.93%
CAS. Nr.: 83846-83-7
Formel: C₂₆H₂₈FN₃O₉
Molecular Weight:545.51

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ketanserin tartrate Chemical Structure

CAS. Nr.: 83846-83-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Ketanserin (R41468) tartrate is a selective 5-HT2 receptor antagonist. Ketanserin tartrate also blocks hERG current (I_hERG) in a concentration-dependent manner (IC₅₀=0.11 μM).

IC₅₀ & Target

5-HT₂ Receptor

hERG current

0.11 μM (IC₅₀)

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

In Vitro

Ketanserin tartrate at 0.3 μM inhibits the voltage-dependent step current (I_hERG.step) and tail current (I_hERG.tail) of hERG channels with a 5-min exposure^[1].
The synergistic effect observed for AA with 5-HT is, also, blocked by the 5-HT receptor blockers cyproheptadine (IC₅₀=22.0±7 μM), Ketanserin tartrate (IC₅₀=152±23 μM). Ketanserin (50-350 μM) inhibits the synergism by blocking the receptor in a dose-dependent manner. The IC₅₀ value of Cyproheptadine is 22±7 μM and Ketanserin is 152±23 μM^[2]. Ketanserin tartrate inhibits platelet aggregation with an IC₅₀ of 240 (169-339) nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ketanserin tartrate is a 5-HT2A receptor antagonist. Ketanserin significantly reduces BDNF protein levels in numerous brain regions (CA1 and CA3 of the hippocampus, prefrontal cortex, central amygdaloid nucleus, dorsomedial hypothalamic nucleus, dentate gyrus, shell of the nucleus accumbens and midbrain periaqueductal gray). 5-HT_2A antagonist Ketanserin tartrate can significantly reduce BDNF mRNA levels in various brain regions^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 83846-83-7
Appearance Solid
Molecular Weight 545.51
Formel C₂₆H₂₈FN₃O₉
Color White to off-white
SMILES

O=C(C1=CC=CC=C1N2)N(CCN3CCC(C(C4=CC=C(F)C=C4)=O)CC3)C2=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Synonyms

R41468 tartrate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (18)

All Bio/Physico-chemical AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

J Ethnopharmacol

Phytomedicine Fructus Aurantii-derived two absorbed compounds unlock antidepressant and prokinetic multi-functions via modulating 5-HT3/GHSR. [Abstract]

2024 Apr 6:323:117703. PMID: 38185260
Neurobiol Dis

Glial expression of Drosophila UBE3A causes spontaneous seizures that can be modulated by 5-HT signaling. [Abstract]

2024 Oct 1:200:106651. PMID: 39197537

Ketanserin tartrate purchased from MedChemExpress. Usage Cited in: Neurobiol Dis. 2024 Oct 1:200:106651. [Abstract]

Representative activity patterns were determined by HMC in control-diet repo > w¹¹¹⁸ flies, and repo > dube3a flies fed Ketanserin (KET) (0.4 μM).

Ketanserin tartrate purchased from MedChemExpress. Usage Cited in: Neurobiol Dis. 2024 Oct 1:200:106651. [Abstract]

Ketanserin (KET) (0.04-0.4 μM) decreased immobilization time and the rate of high-velocity events of repo > dube3a flies during the high-temperature period.

Ketanserin tartrate purchased from MedChemExpress. Usage Cited in: Neurobiol Dis. 2024 Oct 1:200:106651. [Abstract]

Representative traces of DLM spiking in repo > dube3a flies treated with Ketanserin (KET) (0.04-0.4 μM) compared to repo > dube3a and repo > w¹¹¹⁸ flies reared on the control diet.

Ketanserin tartrate purchased from MedChemExpress. Usage Cited in: Neurobiol Dis. 2024 Oct 1:200:106651. [Abstract]

Ketanserin (KET) (0.04-0.4 μM) reduced overall firing frequency and bursting in repo > dube3a flies.
Int J Mol Sci

Identification and Pharmacological Characterization of Two Serotonin Type 7 Receptor Isoforms from Mythimna separata. [Abstract]

2022 Dec 30;24(1):655. PMID: 36614100

Ketanserin tartrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Dec 30;24(1):655. [Abstract]

Ketanserin (40 μM) decreased the 5-HT induced response in HEK293 cells expressing Msep5-HT7L or Msep5-HT7S receptors.
Pest Manag Sci

Pharmacological characterization and functional roles of the 5-HT7 receptor for pheromone sensitivity and mating in Helicoverpa armigera. [Abstract]

2025 May 13. PMID: 40364570
Mol Pain

Mast cell-5-HT-HTR2A axis involvement in chronic itch induced by SADBE. [Abstract]

2026 Jan-Dec:22:17448069251410452. PMID: 41378780
Neuroendocrinology

Peripheral 5-HT mediates GnIH-induced feeding behavior and energy metabolism disorder in chickens via the 5-HT2C receptor. [Abstract]

2024;114(8):749-774. PMID: 38718758
Patent

US20240376052A1.
Patent

US20240383850A1.
Patent

US20240279226A1.
bioRxiv

Glial expression of Drosophila UBE3A causes spontaneous seizures modulated by 5-HT signaling. [Abstract]

2024 Feb 9:2024.02.08.579543. PMID: 38370819
bioRxiv

2024 Jan 20.
Patent

US20230203070A1.
University of Cambridge

2023 Feb.
Patent

US20220324889A1.
Patent

US20220289774A1.
Authorea

September 19, 2022.
Patent

US20220017549A1.
Patent

US20220017550A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (45.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8331 mL

9.1657 mL

18.3315 mL

5 mM

0.3666 mL

1.8331 mL

3.6663 mL

10 mM

0.1833 mL

0.9166 mL

1.8331 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

The established HEK 293 cell line stably expressing hERG channels is cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum, 400 μg/mL G418. The HEK 293 cell line stably expressing recombinant human cardiac KCNQ1/KCNE1 channel current (I_Ks) is maintained in DMEM containing 10% foetal bovine serum and 100 μg/mL hygromycin. Cells used for electrophysiology are seeded on a glass coverslip. The mutant hERG channels are constructed, and are transiently expressed in HEK 293 cells using 10 μL of Lipofectamine 2000 with 4 μg of hERG mutant cDNA in pCDNA3 vector^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Rat^[4]
A total of 155 specific-pathogen-free 2-month-old male Sprague-Dawley rats, weighing 180-220 g, are used. The rats are randomly divided into the following six groups: 5-HT_1A receptor agonist (8-OH-DPAT) PS group (DPAT-PS group, n=30); 5-HT_1A receptor antagonist (MDL73005) PS group (MDL-PS group, n=30); 5-HT_2A receptor agonist (DOI) PS group (DOI-PS group, n=30); 5-HT_2A receptor antagonist (Ketanserin) PS group (Ketan-PS group, n=30); the solvent control no-stress group (0.9% physiological saline group, CON group); and the PS only group (PS group, n=30). The DPAT-PS, MDL-PS, DOI-PS, Ketan-PS and PS groups are further divided into six subgroups (n=5 each) according to the time between the stress and analysis; immediately after stress, and 0.5, 1, 2, 6 and 24 hours after stress. The CON group (n=5) receive normal feed. For the Ketan-PS group, Ketanserin, dissolved in 0.9% physiological saline, is injected intraperitoneally at 5 mg/kg at 1 hour before each stress exposure.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tang Q, et al. The 5-HT2 antagonist Ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels. Br J Pharmacol. 2008 Oct;155(3):365-73. [Content Brief]

[2]. Khan N, et al. Investigation of cyclooxygenase and signaling pathways involved in human platelet aggregation mediated by synergistic interaction of various agonists. Drug Des Devel Ther. 2015 Jul 6;9:3497-506. [Content Brief]

[3]. Kekewska A, et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells. J Pharmacol Exp Ther. 2012 Feb;340(2):369-76. [Content Brief]

[4]. Jiang DG, et al. Serotonin regulates brain-derived neurotrophic factor expression in select brain regions during acute psychological stress. Neural Regen Res. 2016 Sep;11(9):1471-1479. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8331 mL	9.1657 mL	18.3315 mL	45.8287 mL
	5 mM	0.3666 mL	1.8331 mL	3.6663 mL	9.1657 mL
	10 mM	0.1833 mL	0.9166 mL	1.8331 mL	4.5829 mL
	15 mM	0.1222 mL	0.6110 mL	1.2221 mL	3.0552 mL
	20 mM	0.0917 mL	0.4583 mL	0.9166 mL	2.2914 mL
	25 mM	0.0733 mL	0.3666 mL	0.7333 mL	1.8331 mL
	30 mM	0.0611 mL	0.3055 mL	0.6110 mL	1.5276 mL
	40 mM	0.0458 mL	0.2291 mL	0.4583 mL	1.1457 mL

Bioz

Keywords

Ketanserin tartrate

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ketanserin tartrate

Publications Citing Use of MedChemExpress (MCE) Ketanserin tartrate

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen